Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 231

1.

Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences.

Kimbung S, Kovács A, Bendahl PO, Malmström P, Fernö M, Hatschek T, Hedenfalk I.

Mol Oncol. 2014 Feb;8(1):119-28. doi: 10.1016/j.molonc.2013.10.002.

2.

Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer.

Kimbung S, Johansson I, Danielsson A, Veerla S, Egyhazi Brage S, Frostvik Stolt M, Skoog L, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B, Loman N, Malmström PO, Söderberg M, Walz TM, Fernö M, Hatschek T, Hedenfalk I; TEX study group..

Clin Cancer Res. 2016 Jan 1;22(1):146-57. doi: 10.1158/1078-0432.CCR-15-0487.

3.

Evaluation of vascular endothelial growth factor as a prognostic marker for local relapse in early-stage breast cancer patients treated with breast-conserving therapy.

Moran MS, Yang Q, Goyal S, Harris L, Chung G, Haffty BG.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1236-43. doi: 10.1016/j.ijrobp.2010.07.031.

PMID:
21093162
4.

[Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].

Li Q, Xu BH, Zhang P, Li Q, Yuan P, Wang JY, Luo Y, Ma F, Fan Y, Li Q.

Zhonghua Zhong Liu Za Zhi. 2013 Mar;35(3):207-11. doi: 10.3760/cma.j.issn.0253-3766.2013.03.010. Chinese.

PMID:
23880002
5.

[Claudins as prognostic factors of breast cancer].

Szász MA.

Magy Onkol. 2012 Sep;56(3):209-12. doi: MagyOnkol.2012.56.3.209. Hungarian.

6.

Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.

Falck AK, Bendahl PO, Chebil G, Olsson H, Fernö M, Rydén L.

Breast Cancer Res Treat. 2013 Jul;140(1):93-104. doi: 10.1007/s10549-013-2617-8.

PMID:
23807420
7.

Internal mammary lymph node recurrence: rare but characteristic metastasis site in breast cancer.

Chen L, Gu Y, Leaw S, Wang Z, Wang P, Hu X, Chen J, Lu J, Shao Z.

BMC Cancer. 2010 Sep 7;10:479. doi: 10.1186/1471-2407-10-479.

8.

Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.

Park YH, Lee S, Cho EY, Choi YL, Lee JE, Nam SJ, Yang JH, Ahn JS, Im YH.

Cancer Chemother Pharmacol. 2010 Aug;66(3):507-16. doi: 10.1007/s00280-009-1190-7.

PMID:
19956951
9.

Prognostic and metastatic value of phosphatase of regenerating liver-3 in invasive breast cancer.

Hao RT, Zhang XH, Pan YF, Liu HG, Xiang YQ, Wan L, Wu XL.

J Cancer Res Clin Oncol. 2010 Sep;136(9):1349-57. doi: 10.1007/s00432-010-0786-y.

PMID:
20140626
10.

Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis.

Loehberg CR, Almstedt K, Jud SM, Haeberle L, Fasching PA, Hack CC, Lux MP, Thiel FC, Schrauder MG, Brunner M, Bayer CM, Hein A, Heusinger K, Heimrich J, Bani MR, Renner SP, Hartmann A, Beckmann MW, Wachter DL.

Breast Cancer Res Treat. 2013 Apr;138(3):899-908. doi: 10.1007/s10549-013-2460-y.

PMID:
23479421
11.

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.

12.

High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.

Shubbar E, Helou K, Kovács A, Nemes S, Hajizadeh S, Enerbäck C, Einbeigi Z.

BMC Cancer. 2013 Feb 1;13:47. doi: 10.1186/1471-2407-13-47.

13.

Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?

Falck AK, Fernö M, Bendahl PO, Rydén L.

World J Surg. 2010 Jul;34(7):1434-41. doi: 10.1007/s00268-010-0499-z.

PMID:
20213203
14.

Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.

Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, Park KH.

Am J Clin Oncol. 2013 Jun;36(3):224-31. doi: 10.1097/COC.0b013e3182467d90.

PMID:
22495453
15.
16.

β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases.

Bleckmann A, Conradi LC, Menck K, Schmick NA, Schubert A, Rietkötter E, Arackal J, Middel P, Schambony A, Liersch T, Homayounfar K, Beißbarth T, Klemm F, Binder C, Pukrop T.

Clin Exp Metastasis. 2016 Apr;33(4):309-23. doi: 10.1007/s10585-016-9780-3.

17.

Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression?

Rack B, Janni W, Gerber B, Strobl B, Schindlbeck C, Klanner E, Rammel G, Sommer H, Dimpfl T, Friese K.

Breast Cancer Res Treat. 2003 Nov;82(2):83-92.

PMID:
14692652
18.

p53 as an independent prognostic marker in lymph node-negative breast cancer patients.

Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U.

J Natl Cancer Inst. 1993 Jun 16;85(12):965-70.

PMID:
8496982
19.
20.

[Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].

Zhang P, Xu BH, Ma F, Li Q, Yuan P, Wang JY, Zhang P.

Zhonghua Zhong Liu Za Zhi. 2011 May;33(5):381-4. Chinese.

PMID:
21875471

Supplemental Content

Support Center